Please ensure Javascript is enabled for purposes of website accessibility

Fighting Hard to Keep a Blockbuster

By Brian Orelli, PhD - Updated Apr 6, 2017 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sanofi is suing the FDA. Did you expect something different?

Lawsuits between branded drugmakers and their generic rivals happen almost every week it seems. Often it takes a lawsuit to figure out whether a patent is valid.

But the lawsuit filed by sanofi-aventis (NYSE: SNY) over a recently approved generic version of Lovenox is different. The French drugmaker is suing the U.S. Food and Drug Administration, asking the court to force the agency to take back the approval of the competing generic. Now that takes gumption.

Of course Lovenox, the drug in question, is a multibillion dollar franchise, and the complexity of the active ingredient makes Sanofi's argument somewhat reasonable. But still, claiming the FDA's decision will create "irreparable harm" is a slap in the face of the agency's scientific staff, a staff that Sanofi needs to approve the drugs currently in its pipeline. Wyeth sued the agency last year making a similar claim about generics, but the company was in the midst of disappearing into Pfizer (NYSE: PFE), so there was less risk of long-term repercussions.

Momenta Pharmaceuticals (Nasdaq: MNTA) fell 12% yesterday, which is a little surprising because the company said on Friday that they had expected the challenge from Sanofi. The company says the judge didn't invoke an injunction stopping its marketing partner, Novartis (NYSE: NVS), from selling the drug. A hearing is scheduled on August 17 to rule on a preliminary injunction.

Obviously anything can happen with the judge, but it's not like the FDA has taken this decision lightly, having taken many years to approve the generic. The agency has even passed over other applications -- so far -- from Teva Pharmaceuticals (Nasdaq: TEVA) and Amphastar Pharmaceuticals, so it's not a blanket endorsement that everyone has the capacity to make generic Lovenox.

Sure, there's some risk of Momenta losing its only product on the market, but that was theoretically true before Sanofi filed its lawsuit. If you're OK with that risk, Momenta is a little cheaper today than it was at the height of the post-approval euphoria.

Looking for more upcoming binary events? Jim Mueller highlights three to keep your eye on.

Pfizer is a Motley Fool Inside Value selection. Momenta Pharmaceuticals is a Rule Breakers pick. Novartis is a Global Gains recommendation. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
Sanofi
SNY
$49.22 (-0.99%) $0.49
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.17 (-0.19%) $0.10
Novartis AG Stock Quote
Novartis AG
NVS
$85.86 (0.34%) $0.29
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$11.00 (2.88%) $0.31
Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.
MNTA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.